Ethamsylate

Global Calcium is one of the leading manufacturers and exporters of Ethamsylate CAS no. 2624-44-4, API, (Active Pharmaceutical Ingredient). We support the customers with exhaustive documentation. As a USDMF & EU-GMP certified global company and an established hallmark for pharmaceutical standards, Global Calcium has stood the test of time since its inception in 1979.

As manufacturer of Ethamsylate we hereby state the following facts about the drug:

Indications for Use

Ethamsylate exerts hemostatic action by acting on the first step of hemostasis by improving platelet adhesiveness and restoring capillary resistance. It decreases bleeding time and increases platelet aggregation. It reduces capillary bleeding when platelets are adequate.

Drug Information

Periventricular hemorrhage: Ethamsylate is licensed for the prophylaxis and treatment of periventricular hemorrhage in neonates, in whom it is apparently effective. Well-controlled clinical trials showed therapeutic efficacy of ethamsylate in periventricular hemorrhage in very low birth weight babies and surgical or postsurgical capillary bleeding.

Dysfunctional uterine bleeding: Well-controlled clinical trials clearly showed the therapeutic efficacy of ethamsylate in dysfunctional uterine bleeding, with the magnitude of blood-loss reduction being directly proportional to the severity of the menorrhagia.

Postoperative hemorrhage:  Ethamsylate is also used to prevent or treat excessive internal bleeding after a surgery is performed.

The place of ethamsylate as a hemostatic agent is that of a mild but well-tolerated drug, particularly useful in dysfunctional uterine bleeding when contraception is not needed.

Global Calcium is a leading manufacturer of this drug. We manufacture this pharmaceutical drug and make it available to domestic and overseas market